# Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer

> **NCT04643366** · PHASE2 · RECRUITING · sponsor: **Virginia Commonwealth University** · enrollment: 54 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** Chemotherapy
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT04643366
- **Lead sponsor:** Virginia Commonwealth University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-28
- **Primary completion:** 2028-01-31
- **Final completion:** 2033-01-31
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04643366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04643366, "Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04643366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*